NEW YORK , June 27, 2024 /PRNewswire/ -- The global binge-eating disorder treatment market size is estimated to grow by USD 568.7 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.
78% during the forecast period. Increasing prevalence of binge-eating disorder is driving market growth, with a trend towards development and approval of new drugs. However, side effects of binge-eating disorder drugs poses a challenge.
Key market players include Alvogen Iceland ehf, Bausch Health Companies Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli Lilly and Co.
, Johnson and Johnson Services Inc., Lupin Ltd., Omeros Corp.
, Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd.
, Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals Holding Corp.
, Tryp Therapeutics Inc., Viatris Inc., VIVUS LLC, and Walden Behavioral Care.
Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Binge-Eating Disorder Treatment Market Scope Report Coverage Details Base year 2023 Historic period 2018 - 2022 Forecast period 2024-2028 Growth momentum & CAGR Accelerate at a CAGR of 6.78% Market growth 2024-2028 USD 568.7 million Market structure Concentrated YoY growth 2022-2023 (%) 6.
24 Regional analysis North America, Europe, Asia, and Rest of World (ROW) Performing market contribution North America at 35% Key .
